Nutriband (NTRB) to Release Quarterly Earnings on Tuesday

Key Points

• Nutriband (NTRB) is set to release its quarterly earnings report on Tuesday, September 2nd, with analysts expecting an earnings per share (EPS) of ($0.17) and revenue of $0.705 million.
• In its last earnings report on May 30th, Nutriband reported an EPS of ($0.12), beating estimates, but had a negative return on equity of 68.25% and a negative net margin of 415.93%.
• The company's stock opened at $6.41, with a market cap of $71.47 million, reflecting a 12-month trading range between a low of $3.72 and a high of $11.78.

Nutriband (NASDAQ:NTRB - Get Free Report) is expected to announce its results before the market opens on Tuesday, September 2nd. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $0.7050 million for the quarter.

Nutriband (NASDAQ:NTRB - Get Free Report) last issued its earnings results on Friday, May 30th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $0.71 million. Nutriband had a negative net margin of 415.93% and a negative return on equity of 68.25%. On average, analysts expect Nutriband to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nutriband Trading Down 0.9%

NASDAQ:NTRB traded down $0.06 during trading hours on Friday, reaching $6.47. The company's stock had a trading volume of 7,398 shares, compared to its average volume of 189,340. The firm has a 50-day simple moving average of $7.57 and a 200-day simple moving average of $6.76. Nutriband has a 1 year low of $3.72 and a 1 year high of $11.78. The firm has a market capitalization of $72.14 million, a price-to-earnings ratio of -7.19 and a beta of 1.13. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.48 and a current ratio of 3.71.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.